Drugs / Allogenic Human Islet Cells
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03746769 | Jul 2019 → Aug 2028 expected | type 1 diabetes mellitus | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01909245 | Oct 2013 → Sep 2026 expected | type 1 diabetes mellitus | City of Hope Medical Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogenic Human Islet Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03746769 ↗ |
| Modality | Cell therapy | “islet cell transplantation” NCT01909245 ↗ |
| Route | Other | “Intraportal (into the liver) infusion of islet cells” NCT01909245 ↗ |